Showing 6171-6180 of 9140 results for "".
- LEO Pharma's Adbry Approved for Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-approved-for-moderate-to-severe-ad/2461020/FDA has approved Adbry™ (tralokinumab-ldrm) from LEO Pharma Inc. for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the
- Obagi Enters Device Arena with The Skintrinsiq Systemhttps://practicaldermatology.com/news/obagi-enters-device-arena-with-the-skintrinsiq-system/2461019/Obagi is launching the Skintrinsiq device, its first entry into the complementary skincare device market. The Skintrinsiq system extracts impurities then infuses Obagi skincare products via treatment protocols customized for individual skincare needs. "The uni
- Lilly's Lebrikizumab Plus Topical Corticosteroids Offer Improvement and Itch Relief in Atopic Dermatitishttps://practicaldermatology.com/news/lillys-lebrikizumab-plus-topical-corticosteroids-offer-improvement-and-itch-relief-in-atopic-dermatitis/2461015/Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). By Week 16, the study met all primary and k
- Otezla Becomes First Oral Psoriasis Treatment Approved Across All Disease Severitieshttps://practicaldermatology.com/news/otezla-becomes-first-oral-psoriasis-treatment-approved-across-all-disease-severities/2461014/Otezla® (apremilast) from Amgen is now approved for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. This expanded indication makes Otezla the first and only oral treatment approved 
- Allergan Aesthetics Completes Acquisition of Solitonhttps://practicaldermatology.com/news/allergan-aesthetics-completes-acquisition-of-soliton/2461013/It’s official: Allergan Aesthetics, an AbbVie company, completed its acquisition of Soliton, Inc. The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include the RESONIC device.
- FDA Accepts sNDA for Incyte's Opzelura for Vitiligohttps://practicaldermatology.com/news/fda-accepts-snda-for-incytes-opzelura-for-vitiligo/2461009/FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical JAK inhibitor from Incyte, as a potential treatment for adolescents and adults with vitiligo. The sNDA is supported by data from the Phase 3 TRuE-V cl
- Top Researcher of Itch and Inflammatory Skin Conditions to Join Mount Sinai’s Department of Dermatologyhttps://practicaldermatology.com/news/top-researcher-of-itch-and-inflammatory-skin-conditions-to-join-mount-sinais-department-of-dermatology/2461006/One of the top researchers worldwide studying itch and inflammatory skin conditions, Brian S. Kim, MD, MTR, FAAD, will join Mount Sinai Health System as Director of the newly established Mark Lebwohl Center for Neuroinflammation and Sensation. Dr. Kim will also be Vice Chair of Research of the Ki
- Tapinarof Improves Plaque Psoriasis in Phase 3 Trialshttps://practicaldermatology.com/news/tapinarof-improves-plaque-psoriasis-in-phase-3-trials/2461004/Tapinarof performed well in two Phase 3 plaque psoriasis trials, according to research published in the New England Journal of Medicine. “This study report
- Derms Give Back: Destination Healthy Skin Wraps Up Its 2021 Journeyhttps://practicaldermatology.com/news/derms-give-back-destination-healthy-skin-wraps-up-its-2021-journey/2461003/Destination Healthy Skin, The Skin Cancer Foundation’s mobile skin cancer education and screening program, conducted 920 free skin cancer screenings aboard the Foundation’s 38-foot Destination Healthy Skin RV. Approximately 4,000 participants attend
- JAK Inhibitor Combo Shows Promise in Alopecia Areatahttps://practicaldermatology.com/news/jak-inhibitor-combo-shows-promise-in-alopecia-areata/2461002/Ritlecitinib and brepocitinib show significant improvement in scalp alopecia areata biomarkers, according to a phase 2a clinical trial published inthe Journal of Allergy and Clinical Immunology. Rese